Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry
Authors:
- 1 May 1993
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 3 (5) , 875-880
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Hybrid cholecystokinin-A antagonists based on molecular modeling of lorglumide and L-364,718Journal of Medicinal Chemistry, 1992
- Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activityEuropean Journal of Pharmacology, 1991
- Quinazolinone cholecystokinin-B receptor ligandsJournal of Medicinal Chemistry, 1991
- Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity.Proceedings of the National Academy of Sciences, 1990
- Novel glutamic acid-derived cholecystokinin receptor ligandsJournal of Medicinal Chemistry, 1990
- Cholecystokinin antagonists. Synthesis and biological evaluation of 3-substituted benzolactamsJournal of Medicinal Chemistry, 1989
- Hybrid cholecystokinin (CCK) antagonists: new implications in the design and modification of CCK antagonistsJournal of Medicinal Chemistry, 1989
- Benzodiazepine gastrin and brain cholecystokinin receptor ligands; L-365,260Journal of Medicinal Chemistry, 1989
- Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonistsJournal of Medicinal Chemistry, 1988
- Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.Proceedings of the National Academy of Sciences, 1986